MEK162 and RAF265 in Adult Patients With Advanced Solid Tumors Harboring RAS or BRAFV600E Mutations
NCT01352273
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
69
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Solid Tumors
Interventions
DRUG:
MEK162 + RAF265
Sponsor
Array Biopharma, now a wholly owned subsidiary of Pfizer